FHIR IG analytics

Resources that use this resource

No resources found

Resources that this resource uses

No resources found

Narrative

Note: links and images are rebased to the (stated) source

Source1

{
  "resourceType": "Evidence",
  "id": "179635",
  "meta": {
    "versionId": "7",
    "lastUpdated": "2024-12-13T21:07:33.593Z",
    "profile": [
      "http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-participant-flow-evidence"
    ]
  },
  "language": "en",
  "text": {
    "status": "empty",
    "div": "<!-- snip (see above) -->"
  },
  "extension": [
    {
      "url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status",
      "valueCodeableConcept": {
        "coding": [
          {
            "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type",
            "code": "active",
            "display": "Active"
          }
        ]
      }
    }
  ],
  "url": "https://fevir.net/resources/Evidence/179635",
  "identifier": [
    {
      "type": {
        "coding": [
          {
            "system": "http://terminology.hl7.org/CodeSystem/v2-0203",
            "code": "ACSN",
            "display": "Accession ID"
          }
        ],
        "text": "FEvIR Object Identifier"
      },
      "system": "https://fevir.net/FOI",
      "value": "179635",
      "assigner": {
        "display": "Computable Publishing LLC"
      }
    }
  ],
  "name": "ComparativeParticipantFlowEvidence_Dropout_due_to_stopping_intervention_Lofexidine_vs_Placebo_in_opioid_detoxification_trial",
  "title": "ComparativeParticipantFlowEvidence: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial",
  "citeAs": "ComparativeParticipantFlowEvidence: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial [Database Entry: FHIR Evidence Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179635. Revised 2024-05-16. Available at: https://fevir.net/resources/Evidence/179635. Computable resource at: https://fevir.net/resources/Evidence/179635#json.",
  "status": "active",
  "author": [
    {
      "name": "Brian S. Alper"
    }
  ],
  "publisher": "Computable Publishing LLC",
  "contact": [
    {
      "telecom": [
        {
          "system": "email",
          "value": "support@computablepublishing.com"
        }
      ]
    }
  ],
  "useContext": [
    {
      "code": {
        "system": "https://fevir.net/resources/CodeSystem/179423",
        "code": "evidence-communication",
        "display": "Evidence Communication"
      },
      "valueCodeableConcept": {
        "coding": [
          {
            "system": "https://fevir.net/resources/CodeSystem/179423",
            "code": "ComparativeParticipantFlowEvidence",
            "display": "ComparativeParticipantFlowEvidence"
          }
        ]
      }
    }
  ],
  "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/",
  "relatesTo": [
    {
      "type": "derived-from",
      "targetReference": {
        "reference": "Citation/179637",
        "type": "Citation",
        "display": "18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal"
      }
    }
  ],
  "description": "Dropout due to stopping intervention 18/33 with Lofexidine vs. 12/35 with Placebo in opioid detoxification trial",
  "variableDefinition": [
    {
      "description": "Participants in the opioid detoxification trial",
      "variableRole": "population"
    },
    {
      "description": "GroupAssignment: Lofexidine vs. Placebo",
      "variableRole": "exposure",
      "comparatorCategory": "false"
    },
    {
      "description": "Dropout due to stopping intervention",
      "variableRole": "outcome",
      "observed": {
        "reference": "EvidenceVariable/179636",
        "type": "EvidenceVariable",
        "display": "PartiicipantFlowMeasure: Dropout due to stopping intervention"
      }
    }
  ],
  "statistic": [
    {
      "description": "18/33 (54.5%) with Lofexidine vs. 12/35 (34.3%) with Placebo (relative risk 1.59, p < 0.01)",
      "statisticType": {
        "coding": [
          {
            "system": "https://fevir.net/sevco",
            "code": "STATO:0000245",
            "display": "Risk Ratio"
          }
        ]
      },
      "quantity": {
        "value": 1.59
      },
      "numberAffected": 30,
      "sampleSize": {
        "numberOfParticipants": 68
      },
      "attributeEstimate": [
        {
          "description": "p < 0.01",
          "type": {
            "coding": [
              {
                "system": "https://fevir.net/sevco",
                "code": "STATO:0000700",
                "display": "p-value"
              }
            ]
          },
          "quantity": {
            "value": 0.01,
            "comparator": "<"
          }
        }
      ]
    }
  ]
}